OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for collecting and generating evidence for new medical products to show improvements in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer (CRPC) is a chronic disease with high importance for patient HRQoL.  The objective of this study was to review, analyze, and understand trends in the PRO instruments used in patients with CRPC. METHODS: A systematic literature search for CRPC randomized controlled trials (RCTs) with PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was collected for the study size, interventions, year, PRO instrument, and results for PROs. Analysis was conducted to identify trends in commonly used PRO instruments and categorize results as positive, neutral or negative. RESULTS: Ten RCTs with a total of 5797 patients were identified. In these studies there were 13 different PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used in 1,091 patients). Six studies reported positive results with improvement in quality of life symptoms (QoL) versus comparator treatments. Fours studies reported results with deterioration in (QOL). Three studies reported improvement in pain scores. CONCLUSIONS: Patients with CRPC have relatively longer survival and hence QoL is an important consideration for these patients. PRO instruments such as FACT-P and EQC-30 have been commonly used to generate evidence to show which therapies improve patient QoL.